# DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)

> **NCT02574845** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Metformin HCl
- **DRUG:** Furosemide

## Key facts

- **NCT ID:** NCT02574845
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2015-12-09
- **Final completion:** 2015-12-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02574845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02574845, "DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02574845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*